drugset / Trial / NCT07756294

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294 ↗

Phase 2 Not yet recruiting 30 enrolled Wake Forest University Health Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.

Timeline

Start
2026-11
Primary completion
2028-04
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg —
Subject Insulin Protein / enzyme biologic 40 iu Intranasal

Indications